Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C M Gibson

Showing results (31-40 of 98) with videos related to

Pageof 10
Sort By:
American Heart Journal|August 1, 1994
Complications and long-term outcome after percutaneous coronary angioplasty in chronic hemodialysis patientsW H Ahmed, S J Shubrooks, C M Gibson, et al.
Spinal Cord|June 7, 2014
Hydronephrosis: an unusual complication of neurogenic bowel in a patient with spinal cord injury: a case reportL P Lai, C M Gibson-Gill, G Gombas, et al.
The American Journal of Cardiology|May 15, 1992
Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trialsC M Gibson, T Sandor, P H Stone, et al.
The American Journal of Cardiology|May 30, 1998
Impact of injection rate on the Thrombolysis in Myocardial Infarction (TIMI) trial frame countJ T Dodge, M Rizzo, M Nykiel, et al.
The American Journal of Cardiology|October 12, 2000
Use of the thrombolysis in myocardial infarction frame count for the quantitative assessment of transplant-associated arteriosclerosisJ C Fang, S Kinlay, P Wexberg, et al.
Journal of the American College of Cardiology|June 1, 1995
Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research GroupF M Sacks, P H Stone, C M Gibson, et al.
American Heart Journal|December 16, 2014
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendmentAlexander T Cohen, Robert Harrington, Samuel Z Goldhaber, et al.
Journal of the American College of Cardiology|April 1, 1993
Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessmentP C Gordon, C M Gibson, D J Cohen, et al.
Annals of Internal Medicine|October 1, 1996
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study GroupR C Pasternak, L E Brown, P H Stone, et al.
The American Journal of Cardiology|June 17, 2000
Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials)J Llevadot, R P Giugliano, C H McCabe, et al.
Pageof 10

Showing results (31-40 of 98) with videos related to

Sort By:
Pageof 10
American Heart Journal|August 1, 1994
Complications and long-term outcome after percutaneous coronary angioplasty in chronic hemodialysis patientsW H Ahmed, S J Shubrooks, C M Gibson, et al.
Spinal Cord|June 7, 2014
Hydronephrosis: an unusual complication of neurogenic bowel in a patient with spinal cord injury: a case reportL P Lai, C M Gibson-Gill, G Gombas, et al.
The American Journal of Cardiology|May 15, 1992
Quantitative angiographic and statistical methods to assess serial changes in coronary luminal diameter and implications for atherosclerosis regression trialsC M Gibson, T Sandor, P H Stone, et al.
The American Journal of Cardiology|May 30, 1998
Impact of injection rate on the Thrombolysis in Myocardial Infarction (TIMI) trial frame countJ T Dodge, M Rizzo, M Nykiel, et al.
The American Journal of Cardiology|October 12, 2000
Use of the thrombolysis in myocardial infarction frame count for the quantitative assessment of transplant-associated arteriosclerosisJ C Fang, S Kinlay, P Wexberg, et al.
Journal of the American College of Cardiology|June 1, 1995
Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research GroupF M Sacks, P H Stone, C M Gibson, et al.
American Heart Journal|December 16, 2014
Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendmentAlexander T Cohen, Robert Harrington, Samuel Z Goldhaber, et al.
Journal of the American College of Cardiology|April 1, 1993
Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessmentP C Gordon, C M Gibson, D J Cohen, et al.
Annals of Internal Medicine|October 1, 1996
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study GroupR C Pasternak, L E Brown, P H Stone, et al.
The American Journal of Cardiology|June 17, 2000
Degree of residual stenosis in the culprit coronary artery after thrombolytic administration (Thrombolysis In Myocardial Infarction [TIMI] trials)J Llevadot, R P Giugliano, C H McCabe, et al.
Pageof 10